VBLT news Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.